Transcatheter therapies for resistant hypertension: Clinical review

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 6, Issue 8

Peer-Review Report of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Cardiology

ISSN

1949-8462

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Cardiol. Aug 26, 2014; 6(8): 706-712
Published online Aug 26, 2014. doi: 10.4330/wjc.v6.i8.706

Table 1 Renal artery stenting/angioplasty in resistant hypertension

Ref.	Size	Follow up period	Mean SBP reduction with stenting/ angioplasty	Mean SBP reduction with medical therapy	P value
Cooper et al[3] (Coral trial)	947	43 mo	16.6 ± 21.2	15.6 ± 25.8	0.03
Van Jaarsveld et al[7] (DRASTIC trial)	106	12 mo	19	17	0.51
Plouin et al[5] (EMMA trial)	49	6 mo	12 ± 20	8 ± 16	0.46
Webster et al[6]	135	3-54 mo	34	8	0.018

SBP: Systolic blood pressure.

Citation: Lokhandwala A, Dhoble A. Transcatheter therapies for resistant hypertension: Clinical review. World J Cardiol 2014; 6(8): 706-712
URL: https://www.wjgnet.com/1949-8462/full/v6/i8/706.htm
DOI: https://dx.doi.org/10.4330/wjc.v6.i8.706

Lokhandwala A, Dhoble A. Transcatheter therapies for resistant hypertension: Clinical review. World J Cardiol 2014; 6(8): 706-712 [PMID: 25228950 DOI: 10.4330/wjc.v6.i8.706]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.